Increasing incidence of minimal residual cancer in radical prostatectomy specimens

American Journal of Surgical Pathology

Volumn 21, Issue 2, 1997, Pages 174-178

  DiGiuseppe, Joseph A ^a   Sauvageot, Jurgita ^a   Epstein, Jonathan I ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SCREENING; HUMAN; HUMAN TISSUE; MINIMAL RESIDUAL DISEASE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TRANSURETHRAL RESECTION;

ADENOCARCINOMA; HUMANS; MALE; NEOPLASM, RESIDUAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0031044884     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199702000-00006     Document Type: Article

References (13)

1. Bastacky S, Walsh PC, Epstein JI. Needle biopsy associated tumor tracking of adenocarcinoma of the prostate. J Urol 1991;145: 1000-7.
2. Epstein JI, Walsh PC, CarMichael M, Brendler CB. Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
3. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 1995;26:223-9.
4. Goldstein NS, Bégin LR, Grody WW, et al. Minimal or no cancer in radical prostatectomy specimens: report of 13 cases of the "vanishing cancer phenomenon". Am J Surg Pathol 1995;19:1002-9.
5. Labrie F, Cusan L, Gomez J, et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology Symposium 1994;44:29-37.
6. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathologic stage in stage B prostate cancer. J Urol 1989;141:341-5.
7. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358-68.
8. Pummer K, Crawford ED, Daneshgari ED, et al. Hormonal pre-treatment does not affect the final pathologic stage in locally advanced prostate cancer. Urology Symposium 1994;44:38-42.
9. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-85.
10. Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer. J Urol 1995;154:424-8.
11. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-8.
12. Vaillancourt L, Têtu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am J Surg Pathol 1996;20:86-93.
13. Poppel HV, De Ridder D, Elgamal AA, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol 1995;154:429-34.